ALK and non-small cell lung carcinoma: The consistent sensitivity of several ALK mutations demonstrated in our in silico experiments, including I1171N, F1174L, F1174C, F1174I, G1202R, and R1275Q, to lorlatinib, as highlighted by our findings and supported by OncoKB classifications, strongly suggests the potential for therapeutic repurposing of this third-generation ALK inhibitor beyond its current primary indication in NSCLC.